1.Advances of Angiopoietin-Tie axis in vascular and lymphatic system-related diseases.
Rui WANG ; Meijuan HUANG ; Yanyan XU ; Cai YUAN ; Mingdong HUANG ; Longguang JIANG
Chinese Journal of Biotechnology 2021;37(8):2633-2644
Endothelial cells that form the inner layers of both blood and lymphatic vessels are important components of the vascular system and are involved in the pathogenesis of vascular and lymphatic diseases. Angiopoietin (Ang)-Tie axis in endothelial cells is the second endothelium-specific ligand-receptor signaling system necessary for embryonic cardiovascular and lymphatic development in addition to the vascular endothelial growth factor receptor pathway. The Ang-Tie axis also maintains vascular homeostasis by regulating postnatal angiogenesis, vessel remodeling, vascular permeability, and inflammation. Therefore, the dysfunction of this system leads to many vascular and lymphatic diseases. In light of the recent advances on the role of the Ang-Tie axis in vascular and lymphatic system-related diseases, this review summarizes the functions of the Ang-Tie axis in inflammation-induced vascular permeability, vascular remodeling, ocular angiogenesis, shear stress response, atherosclerosis, tumor angiogenesis, and metastasis. Moreover, this review summarizes the relevant therapeutic antibodies, recombinant proteins, and small molecular drugs associated with the Ang-Tie axis.
Angiopoietins
;
Endothelial Cells/metabolism*
;
Humans
;
Lymphatic Diseases
;
Lymphatic System/metabolism*
;
Receptor, TIE-2/metabolism*
;
Signal Transduction
;
Vascular Endothelial Growth Factor A
2.Recent progress in developing of thrombolytic agents for ischemic stroke.
Yanyan XU ; Shanli CHEN ; Dan CHEN ; Shuangzhou PENG ; Yuan CHENG ; Jinyu LI ; Yongkun LI ; Longguang JIANG ; Cai YUAN ; Mingdong HUANG
Chinese Journal of Biotechnology 2020;36(10):2029-2039
Ischemic stroke is a major health crisis causing high mortality and morbidity. The key treatment relies on the rapid intervention to dissolve thrombus, to reduce bleeding side effect and re-canalize clotted blood vessels using clot lysis drugs. Tissue plasminogen activator (tPA) is the only FDA-approved drug for ischemic stroke, but it has many limitations in clinical use. In recent years, the development of thrombolytic drugs and treatment strategies based on tPA has been progressed rapidly. Here we review the recent progress in this field, including the contributions from us and others, to promote the future development of novel thrombolytic drugs.
Brain Ischemia/drug therapy*
;
Fibrinolytic Agents/therapeutic use*
;
Humans
;
Research/trends*
;
Stroke/drug therapy*
;
Thrombolytic Therapy/trends*
;
Tissue Plasminogen Activator/therapeutic use*
3. Clinical analysis of 30 cases of Castleman disease with different types of thoracic involvement
Xiaoxian ZHANG ; Lei JIANG ; Chunyan WANG ; Yingying GU ; Longguang LI ; Tingting XIA ; Ying HUANG ; Peikai HUANG ; Qingling ZHANG
Chinese Journal of Hematology 2020;41(2):149-156
Objective:
To improve the clinical understanding of Castleman disease (CD) with different types of thoracic involvement, including their clinical features, radiological and pathological findings, diagnosis and current treatment strategies.
Methods:
Retrospective analysis of 30 patients diagnosed with CD with thoracic involvement and hospitalized between June 2009 and May 2019 in The First Affiliated Hospital of Guangzhou Medical University was performed. Patients were divided into three groups for subsequent analysis based on the clinical data: CD with bronchiolitis obliterans (BO) , unicentric Castleman disease (UCD) without BO, and multicentric Castleman disease (MCD) without BO.
Results:
Among the 30 patients, there were 5 (16.7%) patients diagnosed with BO, 18 (60.0%) patients had UCD without BO and 7 (23.3%) patients had MCD without BO. The average age of MCD without BO patients was significantly older than that of BO and UCD without BO patients[ (49.29±5.39) ys